Type II monocytes modulate T cell–mediated central nervous system autoimmune disease

[1]  H. Neumann,et al.  TREM2-Transduced Myeloid Precursors Mediate Nervous Tissue Debris Clearance and Facilitate Recovery in an Animal Model of Multiple Sclerosis , 2007, PLoS medicine.

[2]  P. Tonali,et al.  pSTAT1, pSTAT3, and T‐bet expression in peripheral blood mononuclear cells from relapsing‐remitting multiple sclerosis patients correlates with disease activity , 2006, Journal of neuroscience research.

[3]  Lawrence Steinman,et al.  How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis , 2006, Annals of neurology.

[4]  K. Miyake,et al.  Conditional Ablation of MHC-II Suggests an Indirect Role for MHC-II in Regulatory CD4 T Cell Maintenance1 , 2006, The Journal of Immunology.

[5]  H. Weiner,et al.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells , 2006, Nature.

[6]  R. Gold,et al.  Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis. , 2006, Brain : a journal of neurology.

[7]  S. Youssef,et al.  Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. , 2006, The Journal of clinical investigation.

[8]  F. Shi,et al.  Do Th2 cells mediate the effects of glatiramer acetate in experimental autoimmune encephalomyelitis? , 2006, International immunology.

[9]  M. Caligiuri,et al.  STAT‐1‐mediated repression of monocyte interleukin‐10 gene expression in vivo , 2006, European journal of immunology.

[10]  D. Karussis,et al.  Amelioration of experimental colitis by Copaxone is associated with class-II-restricted CD4 immune blocking. , 2006, Clinical immunology.

[11]  R. D. Hatton,et al.  Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages , 2005, Nature Immunology.

[12]  C. Farina,et al.  Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action , 2005, The Lancet Neurology.

[13]  Ningli Li,et al.  Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[14]  R. Arnon,et al.  Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[15]  H. Scharfman,et al.  Brain-derived neurotrophic factor. , 2004, Growth factors.

[16]  M. Duddy,et al.  Type 2 Monocyte and Microglia Differentiation Mediated by Glatiramer Acetate Therapy in Patients with Multiple Sclerosis1 , 2004, The Journal of Immunology.

[17]  C. Farina,et al.  Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. , 2004, Brain : a journal of neurology.

[18]  Clare Baecher-Allan,et al.  Loss of Functional Suppression by CD4+CD25+ Regulatory T Cells in Patients with Multiple Sclerosis , 2004, The Journal of experimental medicine.

[19]  D. Wesemann,et al.  STAT-1α and IFN-γ as Modulators of TNF-α Signaling in Macrophages: Regulation and Functional Implications of the TNF Receptor 1:STAT-1α Complex1 , 2003, The Journal of Immunology.

[20]  H. Link,et al.  Effect of glatiramer acetate (Copaxone) on CD4+CD25high T regulatory cells and their IL-10 production in multiple sclerosis , 2003, Journal of Neuroimmunology.

[21]  S. Khoury,et al.  Critical Role of the Programmed Death-1 (PD-1) Pathway in Regulation of Experimental Autoimmune Encephalomyelitis , 2003, The Journal of experimental medicine.

[22]  H. Weiner,et al.  Myelin Oligodendrocyte Glycoprotein–specific T Cell Receptor Transgenic Mice Develop Spontaneous Autoimmune Optic Neuritis , 2003, The Journal of experimental medicine.

[23]  M. Kapsenberg,et al.  Glatiramer Acetate (Copolymer-1, Copaxone) Promotes Th2 Cell Development and Increased IL-10 Production Through Modulation of Dendritic Cells1 , 2003, The Journal of Immunology.

[24]  T. Nomura,et al.  Control of Regulatory T Cell Development by the Transcription Factor Foxp3 , 2002 .

[25]  D. Wesemann,et al.  STAT-1 alpha and IFN-gamma as modulators of TNF-alpha signaling in macrophages: regulation and functional implications of the TNF receptor 1:STAT-1 alpha complex. , 2003, Journal of Immunology.

[26]  R. Hohlfeld,et al.  Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. , 2002, Brain : a journal of neurology.

[27]  S. Dhib-jalbut,et al.  Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis , 2002, Neurology.

[28]  A. Vandenbark,et al.  Inhibitory Effects of Incomplete Freund's Adjuvant on Experimental Autoimmune Encephalomyelitis , 2002, Autoimmunity.

[29]  Svetlana Ten,et al.  Multiple immuno-regulatory defects in type-1 diabetes. , 2002, The Journal of clinical investigation.

[30]  S. Khoury,et al.  Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. , 2001, The Journal of clinical investigation.

[31]  R. Martin,et al.  Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS , 2001, Multiple sclerosis.

[32]  C. Farina,et al.  Mechanisms of action of glatiramer acetate in multiple sclerosis , 2001, Neurology.

[33]  D. Galas,et al.  Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse , 2001, Nature Genetics.

[34]  F. Nestle.  Dendritic cell vaccination for cancer therapy , 2000, Oncogene.

[35]  A. Meshorer,et al.  Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[36]  C. Farina,et al.  Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[37]  J. Krieger,et al.  Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. , 2000, The Journal of clinical investigation.

[38]  I. Gery,et al.  Copolymer 1 inhibits experimental autoimmune uveoretinitis , 2000, Journal of Neuroimmunology.

[39]  Ethan M. Shevach,et al.  Suppressor Effector Function of CD4+CD25+ Immunoregulatory T Cells Is Antigen Nonspecific , 2000, The Journal of Immunology.

[40]  M. Sela,et al.  Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1 , 1998, Journal of Neuroimmunology.

[41]  N. Van Rooijen,et al.  Immune invasion of the central nervous system parenchyma and experimental allergic encephalomyelitis, but not leukocyte extravasation from blood, are prevented in macrophage-depleted mice. , 1998, Journal of immunology.

[42]  M. Sela,et al.  Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[43]  V. Kuchroo,et al.  B7-2 (CD86) is essential for the development of IL-4-producing T cells. , 1996, International immunology.

[44]  M. Sela,et al.  Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses , 1996, Journal of Neuroimmunology.

[45]  S. Kaufmann,et al.  Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon gamma and tumor necrosis factor alpha , 1995, The Journal of experimental medicine.

[46]  Laurie H Glimcher,et al.  B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy , 1995, Cell.

[47]  C. Janeway,et al.  T cells with two functional antigen-specific receptors. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[48]  Jeffrey A. Cohen,et al.  Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. , 1995, Neurology.

[49]  M. Sela,et al.  Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Susumu Tonegawa,et al.  RAG-1-deficient mice have no mature B and T lymphocytes , 1992, Cell.

[51]  R. Knobler,et al.  T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination , 1985, Nature.

[52]  L. Rorke,et al.  Effect of treatment with copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis (EAE) , 1983, Journal of the Neurological Sciences.